

Clinical Trials in Singapore

Year 2020 Research report


[Location Data](#) [Trial Data](#) [Sponsor Data](#) [Subject Data](#) [Data Search and Analysis](#) [About ACROSS](#)

Location Data

Singapore can be considered as a primary R&D spearhead within the APAC region, with cutting-edge technology, highly skilled clinicians, a solid, advanced infrastructure rivaling the West, as well as drive, commitment, and investment by its forward-thinking government to become one of the preferred clinical research destinations worldwide.



Singapore Demographics Breakdown (2020)^[1]




The Health Sciences Authority (HSA) is the Singaporean regulatory agency for health products. It is responsible for securing the national blood supply and providing scientific guidance on forensic science and medicine.

The regulatory framework that ensures drugs, medical devices, and other health products are up to standards is enforced by the Health Products Regulation Group within the HSA. The group is responsible for pre-market approvals and clinical trials, as well as post-market surveillance.^[4]

Healthcare in Singapore is supervised by the Ministry of Health of the Singapore Government. It largely consists of a government-run universal healthcare system with a significant private healthcare sector.

In addition, financing of healthcare costs is managed through a mixture of direct government subsidies, compulsory savings, national healthcare insurance, and cost sharing.^[2]

Singapore Age Demographics Breakdown (2020)^[3]



Singapore's population is 5,85 million people.^[5] English is the official language of Singapore.


Clinical Trials Regulations may be found on the HSA website at www.hsa.gov.sg/clinical-trials/

Trial Data

Based on data extracted from [ClinicalTrials.gov](https://clinicaltrials.gov), there were 160 clinical trials (including local and bioequivalence studies) initiated in Singapore during the Year 2020. This translates to a 16% decline in the number of clinical trials initiated in comparison with the previous year when a total of 190 studies were initiated.


If one excludes bioequivalence studies and studies without a defined "Phase", there were only 79 clinical trials initiated during the Year 2020 compared to 88 studies initiated in previous year, representing a 10% decline

Breakdown of Clinical Trials in Singapore by Phase (Year 2020)



The majority of clinical trials conducted in Singapore were interventional studies with a 77% market share.


The most frequent phase of clinical trials conducted across the Singaporean sites by number of studies was Phase III.



Breakdown of Clinical Trials in Singapore by Therapeutic Area

The largest number of clinical trials initiated in Singapore during the Year 2020 were related to Oncology (30 studies) and Infectious Diseases (12 studies). Other areas included Gastroenterology, Dermatology, and Cardiology. The majority of clinical trials conducted in Singapore in the Year 2020 were Interventional.

More than one therapeutic area could be assigned to a trial. Observational Clinical trials and Clinical trials without FDA-defined phases (from I to IV) were not included in this chart.



Sponsor Data

By country of origin, the U.S. accounted for the largest number of pharmaceutical sponsored clinical trials initiated in the Year 2020 in Singapore. The headquarters of the sponsor companies which initiated clinical trials in the Year 2020 in Singapore were almost equally split between the U.S. (4 companies) and Europe (5 companies).

At the same time one domestic innovative Singaporean company – **Tychan** – initiated two clinical studies in Singapore – with enrollment of 1,337 patients.

Observational clinical trials and clinical trials without FDA-defined phases (from I to IV) were not counted in this ranking.

More than one Sponsor company may be involved in a clinical trial.

Top-10 Sponsors of Clinical trials in Singapore in Y 2020


Nº	Company Name	Studies	Subjects
1	Eli Lilly	8	11 434
2	Hoffmann-La Roche	6	3 570
3	Novartis	6	3 407
4	Bayer	4	3 756
5	Vir Biotechnology	2	10 120
6	Gilead Sciences	2	6 004
7	AstraZeneca	2	2 299
8	Tychan	2	1 337
9	Actelion	2	1 044
10	Bristol-Myers Squibb	2	796
Combined market share		46%	85%

Subject Data

The overall number of subjects enrolled (or planned to be enrolled) in clinical trials initiated in Singapore during the Year 2020 (including multi-center international studies) significantly increased from 29,610 subjects in the previous year to 51,512 subjects in the Year 2020 with a year on year growth rate of 74%.

At the same time 19,148 from these 51,512 subjects are enrolled (or planned to be enrolled) in just three interventional Phase III studies. All of these three studies are aiming to find an appropriate treatment from COVID-19 coronavirus.

Breakdown of Number of Subjects Enrolled in Singapore by Phase (Year 2020)



* Studies indicated by sponsors as Phase I-II were counted as Phase II; Phase II-III – as Phase III, Phase III-IV – as Phase IV.

Clinical Trials in Singapore

Year 2020 Research report

Data Search and Analysis Approach

All of stats data used in this document were downloaded from the [ClinicalTrials.gov](https://clinicaltrials.gov) website as a .CSV file with the download options listed in the table below.

.CSV file export was completed with the following options:

Number of studies [to download]: all studies.

Select table columns: All available columns.

Select file format: Comma-separated values.

Nº	Item Name	Fields in Pivot Table	Details
1	Breakdown of Clinical Trials Initiated in Singapore by Phase	NCT, Phases	Exclude “Not Applicable” and empty values in “Phase” field
2	Percentage Breakdown of Clinical Trials Initiated in Singapore by Phase	NCT, Phases	Exclude “Not Applicable” and empty values in “Phase” field
3	Breakdown of Clinical Trials Initiated in Singapore by Therapeutic Area	NCT, Conditions, Phases	See below *
4	Sponsors Ranked By Number of Studies and Number of Subjects	NCT, Enrollment, Phases, Sponsor	See below **
5	Breakdown of Interventional vs. Observational Trials in 2020	NCT, Study Type	
6	Breakdown of Number of Subjects Enrolled in Singapore by Phase	NCT, Phases, Enrollment	See below ***

* Use “Phases” filed as a filter. Exclude “Not Applicable” and empty values in “Phase” field. Use a simple Dictionary of Nosologies (see below) to count the number of studies for each nosology.

** Use “Phases” filed as a filter. Exclude “Not Applicable” and empty values in “Phase” field. Use “Number of values” by “NCT Number” field. Use “Sum” by “Enrollment” field. Use decreasing sorting of the table by “NCT Number” field.

*** Exclude “Not Applicable” and empty values in “Phase” field. Use “Number of values” by “NCT Number” field. Use “Sum” by “Enrollment” field.

If you want to use the same source .CSV file used in this report – just let us know via info@across.global and we’ll send it to you.

Dictionary of Nosologies used for Breakdown by Therapeutic Area

Nº	Therapeutic Area	Filter String
1	Gastroenterology	*gastr + colon + liver + cron + nash + pancrea*
2	Hematology	*hema + blood*
3	Dermatology	*derm + skin*
4	Urology	*urolog + nephro*
5	Immunology	*immun*
6	Infectious diseases	*infect + virus*
7	Cardiology	*cardi + heart + stroke*
8	Neurology	*neuro + cognitive*

Nº	Therapeutic Area	Filter String
9	Oncology	*cancer + phoma + noma + tumor + sarcoma*
10	Ophthalmology	*eye + ophtalm*
11	Rheumatology	*rheum + arthr*
12	Endocrinology	*endocrin + insulin + diabete*
13	Mental health	*mental + psych + depress + anxiety*
14	Surgery	*surger + transplant*
15	Geriatrics	*alz + parkins*

About The White Paper

The White Paper is a free publication produced by ACROSS Global (CRO) Alliance for decision makers in the pharmaceutical industry. The document pulls together data from numerous public sources into a single brief document to aid decision makers planning to conduct clinical trials.

About ACROSS Global

ACROSS Global is a global alliance of local contract research organizations successfully operating in 99 countries and covering more than 25 therapy areas.

High recruitment rates combined with innovative technology allows ACROSS partner companies to offer our clients conduct faster, more cost-effective studies without sacrificing quality for our clients.

All of the data contained in this document are actual as of 28-JAN-2021.

For more information or if you would like to review a .CSV file of the data extracted from [ClinicalTrials.gov](https://clinicaltrials.gov) (used in this White Paper) please write to: info@across.global.

All clinical studies conducted by ACROSS Partners conform to Good Clinical Practice (GCP) as well as local and international regulations ensuring the highest level of quality of the final study data.

We apply continuous improvement methodology to our working practices and IT infrastructure – and replace outdated R&D strategies by novel, more efficient approaches to clinical research.